ONCY is back over $1.
Readers may recall our Trinity article. We were watching several pieces of the story to see if they started fitting together.
The CRC combo trial pairing ONCY's Pelareorep with bevacizumab, the active ingredient behind Roche's Avastin, is getting underway. Some interest also appears to be forming around the CEO, known for the Ambrx-Johnson & Johnson deal.
If interested, this report does not make buy/sell recommendations, but we do use the term: just some, NOT too much, especially in spec stocks.
It could be some time before the complete "Trinity" combo is tried. BUT some areas are developing that a larger Pharma could be eyeing in the back rooms of their scientists. No guarantees in spec though.
Afterthought: If the biotech success scenario plays out, just some may be enough as a back burner stock to watch.
Reference:
https://stockstowatch.blogspot.com/2025/09/the-trinity-missing-puzzle-piece-to.html
Stay Watchful.
Jones Report
This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?
________
______________
More later so ....Stay tuned, if you dare!
For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality. Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor.
All in all - we use the word maybe "some", not "too much" and play it accordingly. Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.
With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.
ALL in my humble opinion, scroll down and read more. This site does NOT make Buy / Sell recommendations.
